Hybrid Histone Deacetylase Inhibitor: An Effective Strategy for Cancer Therapy

被引:3
|
作者
Wu, Jiyong [1 ]
Nie, Jing [1 ]
Luan, Yepeng [2 ]
Ding, Yanjiao [1 ]
机构
[1] Shandong Second Prov Gen Hosp, Dept Pharm, Jinan, Shandong, Peoples R China
[2] Qingdao Univ, Med Coll, Sch Pharm, Dept Med Chem, Qingdao, Shandong, Peoples R China
基金
美国国家科学基金会;
关键词
Histone deacetylase; hybrid; multitarget inhibitors; antitumor; cancer therapy; bifunctional agent; SHOCK-PROTEIN; 90; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE NAMPT; HYDROXAMIC ACID-DERIVATIVES; BETA-CARBOLINE ALKALOIDS; NITRIC-OXIDE DONORS; IN-VITRO EVALUATION; DEMETHYLASE; LSD1; PROSTATE-CANCER; HDAC INHIBITORS; ANDROGEN RECEPTOR;
D O I
10.2174/0929867329666220826163626
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Inhibition of histone deacetylases (HDACs) has proven to be an effective strategy for cancer therapy. To date, five histone deacetylase inhibitors (HDACis) have been approved for cancer treatment, and numerous others are undergoing clinical trials. An agent that can simultaneously and effectively inhibit two or more targets may offer greater therapeutic benefits over single-acting agents in preventing resistance to treatment and potentiating synergistic effects. A prime example of a bifunctional agent is the hybrid HDACi. Representative classes of reported hybrid HDACis are reviewed here to shed light on the design of novel hybrid HDACis for cancer therapy.
引用
收藏
页码:2267 / 2311
页数:45
相关论文
共 50 条
  • [41] Histone deacetylase inhibitors in cancer therapy. A review
    Hrabeta, Jan
    Stiborova, Marie
    Adam, Vojtech
    Kizek, Rene
    Eckschlager, Tomas
    BIOMEDICAL PAPERS-OLOMOUC, 2014, 158 (02): : 161 - 169
  • [42] Potential use of histone deacetylase inhibitors in cancer therapy
    Golabek, Karolina
    Strzelczyk, Joanna K.
    Wiczkowski, Andrzej
    Michalski, Marek
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2015, 19 (06): : 436 - 440
  • [43] Recent advances in histone deacetylase targeted cancer therapy
    Hoshino, Isamu
    Matsubara, Hisahiro
    SURGERY TODAY, 2010, 40 (09) : 809 - 815
  • [44] Potential of histone deacetylase inhibitors for the therapy of ovarian cancer
    Guo, Fengyi
    Wang, Hongjing
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] Histone deacetylase inhibitor induced modulation of anti-estrogen therapy
    Thomas, Scott
    Munster, Pamela N.
    CANCER LETTERS, 2009, 280 (02) : 184 - 191
  • [46] Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275
    Annette Altmann
    Michael Eisenhut
    Ulrike Bauder-Wüst
    Annette Markert
    Vasileios Askoxylakis
    Holger Hess-Stumpp
    Uwe Haberkorn
    European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37 : 2286 - 2297
  • [47] Therapy with the Histone Deacetylase Inhibitor Sb939 for Patients with Myelofibrosis
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop M.
    Borthakur, Gautam
    Estrov, Zeev
    Cortes, Jorge E.
    Verstovsek, Srdan
    BLOOD, 2011, 118 (21) : 1651 - 1651
  • [48] Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275
    Altmann, Annette
    Eisenhut, Michael
    Bauder-Wuest, Ulrike
    Markert, Annette
    Askoxylakis, Vasileios
    Hess-Stumpp, Holger
    Haberkorn, Uwe
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 (12) : 2286 - 2297
  • [49] Enhancement of the efficacy of histone deacetylase inhibitor-induced gene therapy
    Chen, Yi-Chieh
    Hwu, Luen
    Liu, Ren-Shyan
    Lin, Kuan-Hung
    Wang, Hsin-Ell
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [50] The novel histone deacetylase inhibitor pracinostat is an effective anti-lymphoma agent
    Mensah, Afua A.
    Spriano, Filippo
    Gaudio, Eugenio
    Tarantelli, Chiara
    Cascione, Luciano
    Aresu, Luca
    Lovati, Emanuela
    Zucca, Emanuele
    Stathis, Anastasios
    Pietra, Claudio
    Bertoni, Francesco
    CANCER RESEARCH, 2018, 78 (13)